455 related articles for article (PubMed ID: 11059764)
1. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
2. CYP17 gene polymorphism and its association in north Indian prostate cancer patients.
Sobti RC; Gupta L; Thakur H; Seth A; Singh SK; Kaur P
Anticancer Res; 2009 May; 29(5):1659-63. PubMed ID: 19443382
[TBL] [Abstract][Full Text] [Related]
3. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
[TBL] [Abstract][Full Text] [Related]
4. CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.
Verla-Tebit E; Wang-Gohrke S; Chang-Claude J
Breast Cancer Res; 2005; 7(4):R455-64. PubMed ID: 15987450
[TBL] [Abstract][Full Text] [Related]
5. A polymorphism in the CYP17 gene is associated with prostate cancer risk.
Gsur A; Bernhofer G; Hinteregger S; Haidinger G; Schatzl G; Madersbacher S; Marberger M; Vutuc C; Micksche M
Int J Cancer; 2000 Aug; 87(3):434-7. PubMed ID: 10897051
[TBL] [Abstract][Full Text] [Related]
6. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
[TBL] [Abstract][Full Text] [Related]
7. Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia.
Tigli H; Yazici H; Dalay N
Res Commun Mol Pathol Pharmacol; 2003; 113-114():307-14. PubMed ID: 15686129
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
[TBL] [Abstract][Full Text] [Related]
9. Lack of association between CYP17 Mspa1 polymorphism and prostate cancer risk: a meta-analysis of 14494 cases and 15971 controls.
Song G; Gu L; Tian F; Bao Q; Tang Z; Wang S
Medicina (Kaunas); 2013; 49(2):51-5. PubMed ID: 23888338
[TBL] [Abstract][Full Text] [Related]
10. A polymorphism in the CYP17 gene relates to the risk of recurrent pregnancy loss.
Sata F; Yamada H; Yamada A; Kato EH; Kataoka S; Saijo Y; Kondo T; Tamaki J; Minakami H; Kishi R
Mol Hum Reprod; 2003 Nov; 9(11):725-8. PubMed ID: 14561815
[TBL] [Abstract][Full Text] [Related]
11. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis.
Ntais C; Polycarpou A; Ioannidis JP
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):120-6. PubMed ID: 12582021
[TBL] [Abstract][Full Text] [Related]
12. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer.
Kumazawa T; Tsuchiya N; Wang L; Sato K; Kamoto T; Ogawa O; Nakamura A; Kato T; Habuchi T
Int J Cancer; 2004 May; 110(1):140-4. PubMed ID: 15054879
[TBL] [Abstract][Full Text] [Related]
13. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
[TBL] [Abstract][Full Text] [Related]
14. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.
Ye Z; Parry JM
Mutagenesis; 2002 Mar; 17(2):119-26. PubMed ID: 11880540
[TBL] [Abstract][Full Text] [Related]
15. [Association between the polymorphism of CYP17 gene and risk of prostate cancer in chinese vigurs men].
Guli MR; Wang JQ; Zhang JX; Deng G
Zhonghua Nan Ke Xue; 2006 Feb; 12(2):120-2. PubMed ID: 16519145
[TBL] [Abstract][Full Text] [Related]
16. No association of the 5' promoter region polymorphism of CYP17 gene with prostate cancer risk.
dos Santos A; Ribeiro ML; Mesquita JC; Carvalho-Salles AB; Hackel C
Prostate Cancer Prostatic Dis; 2002; 5(1):28-31. PubMed ID: 15195127
[TBL] [Abstract][Full Text] [Related]
17. CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China.
Hou L; Xu J; Gao YT; Rashid A; Zheng SL; Sakoda LC; Shen MC; Wang BS; Deng J; Han TQ; Zhang BH; Meyers DA; Fraumeni JF; Hsing AW
Int J Cancer; 2006 Jun; 118(11):2847-53. PubMed ID: 16381022
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism of CYP17 and breast cancer risk in Korean women.
Shin MH; Lee KM; Yang JH; Nam SJ; Kim JW; Yoo KY; Park SK; Noh DY; Ahn SH; Kim B; Kang D
Exp Mol Med; 2005 Feb; 37(1):11-7. PubMed ID: 15761247
[TBL] [Abstract][Full Text] [Related]
19. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T
J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
[TBL] [Abstract][Full Text] [Related]
20. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
Haiman CA; Hankinson SE; Spiegelman D; Colditz GA; Willett WC; Speizer FE; Kelsey KT; Hunter DJ
Cancer Res; 1999 Mar; 59(5):1015-20. PubMed ID: 10070957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
